

09-13-06

18W/15

DOCKET NO.: ALZA-0143

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

George V. Guittard, et al.

Confirmation No.: 8447

Application No.: 10/645,715

Group Art Unit: 1614

Filing Date: August 20, 2003

Examiner: George, Konata M

For: METHOD FOR MANAGEMENT OF INCONTINENCE

EXPRESS MAIL LABEL NO: EL 999318471 US  
DATE OF DEPOSIT: September 11, 2006

EL 999318471US

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☒ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 385, 386 listed on the attached Form PTO-1449 are enclosed herewith.


- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 11, 2006



Wendy A. Choi

Registration No. 36,697

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



Sheet 1 of 1

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
	Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	<b>385</b>	In the United States District Court of Appeals for the Federal Circuit, ALZA Corporation, Plaintiff-Appellant, v. Impax Laboratories, Inc., Defendant-Appellee, Decision-Judgment of Non-Infringement and Invalidity, <b>September 6, 2006</b> , Appeal # 06-1047, 2 pages
	<b>386</b>	In the United States District Court of Appeals for the Federal Circuit, ALZA Corporation, Plaintiff-Appellant, v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc., Defendants-Appellees, Decision, <b>September 6, 2006</b> , Appeal # 06-1019,
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>